At its meeting on 23 January 2023 the Transparency Council adopted opinion No. 12/2023 on the evaluation of the medicine Lorviqua (lorlatinib) under the drug programme “First-line treatment of non-small cell lung cancer with lorlatinib (ICD-10 C34)”.